Scientific Program
08:00
Registration
09:00-09:10
Welcome & Opening Remarks
Prof. Dr. Alexander M.M. Eggermont, Netherlands and Dr. Mario Mandalà, Italy | Congress Chairs
09:10-10:55
Session 1: Keynote Lectures
Chairs: Prof. Dr. Alexander M.M. Eggermont, Netherlands and Dr. Mario Mandalà, Italy
09:10-09:40
Keynote Lecture 1: Artificial Intelligence in Melanoma and Other Skin Cancer Diagnosis
Harald Kittler
Medical University of Vienna, Austria
09:40-09:45
Discussion/Q&A
09:45-10:15
Keynote Lecture 2: New Developments/New Drugs and Strategies in Targeted therapies for Melanoma and NMSC
Reinhard Dummer
University Hospital of Zürich, Switzerland
10:15-10:20
Discussion/Q&A
10:20-10:50
Keynote Lecture 3: Personalized versus non-personalized vaccines
Reinhard Dummer
University Hospital of Zürich, Switzerland
10:50-10:55
Discussion/Q&A
10:55-11:25
Coffee Break, Poster Viewing & Visit the Exhibition
11:25-12:00
Session 2: Short Presentations by Young Investigators
Chair: Prof. Dr. Alexander M.M. Eggermont, Netherlands
11:25-11:35
Circultating tumor DNA (ctDNA) in Stage-III BRAF+ patients: a real-life study in the adjuvant setting
11:35-11:45
Development of a Deep Learning Model for Histopathological Prognostication of Localised Melanoma
11:45-11:55
Genomic mechanisms of aggressive and metastatic phenotypes in non-melanoma skin cancers
11:55-12:00
Discussion/Q&A
12:00-12:30
Industry Symposium Sponsored by MSD
12:00-12:05
Welcome and Introductions
Reinhard Dummer
University Hospital of Zürich, Switzerland
12:05-12:15
Any Prognostic Biomarkers Ready for Use in Early-Stage Melanoma Patients?
Teresa Amaral
University Hospital Tübingen, Germany
Reinhard Dummer
University Hospital of Zürich, Switzerland
12:15-12:25
Why I Do (not) Treat Early-Stage Melanoma?
Reinhard Dummer
University Hospital of Zürich, Switzerland
Teresa Amaral
University Hospital Tübingen, Germany
12:25-12:30
Q&A/Panel Discussion
12:30-13:30
Lunch Break, Poster Viewing & Visit the Exhibition
13:30-14:00
Session 3: Keynote Lecture
Chair: Mario Mandalà, Italy
13:30-13:55
Keynote Lecture 4: Prevention of skin cancers: fact or fiction, limitations vs opportunities
Philippe Autier
International Prevention Research Institute, France
13:55-14:00
Discussion/Q&A
14:00-14:50
Session 4: Melanoma Staging under Scrutiny, current & future developments
Chair: Teresa Amaral, Germany
14:00-14:25
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
Julian Kött
University Medical Center Hamburg, Germany
14:25-14:50
CP-GEP as a tool to identify risk of relapse in stage I/II and Head & Neck Melanoma populations
Teresa Amaral
University Hospital Tübingen, Germany
14:50-15:00
Discussion/Q&A
15:00-15:30
Coffee Break, Poster Viewing & Visit the Exhibition
15:30-16:45
Session 5: What is New in Rare Malignancies
Chair: Mario Mandalá, Italy
15:30-15:55
What’s new in Merkel Cell Carcinoma?
Jürgen Becker
German Cancer Research Center (DKFZ), Germany
15:55-16:20
What’s new in Uveal Melanoma?
Paul Nathan
Mount Vernon Cancer Centre, UK
16:20-16:45
Melanoma in Children and Young Adults
Mario Mandalà
University of Perugia, Santa Maria Misericordia Perugia, Italy
16:45-17:15
Session 6: Keynote Lecture
Chair: Alexander M.M. Eggermont, Netherlands
16:45-17:15
Keynote Lecture 5: Microbiome and Immunotherapy
Laurence Zitvogel
Gustave Roussy Cancer Campus, France
17:15
End of Day One
08:30
Registration
09:00-10:40
Session 7: Adjuvant and Neoadjuvant Therapy in Dermato-Oncology
Chair: Alexander M.M. Eggermont, Netherlands
09:00-09:25
Adjuvant Therapy of Melanoma and the Role for Identifiers of High Risk for Relapse: Consequences for New Trials and Daily Practice
Alexander M.M. Eggermont
Utrecht University, Netherlands
09:25-09:50
Neoadjuvant Immunotherapy the Standard for Stage III and beyond?
Christian Blank
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Netherlands
09:50-10:15
Reducing Surgical Interventions in Melanoma Management
Piotr Rutkowski
Maria Sklodowska-Curie National Research Institute of Oncology, Poland
10:15-10:40
Neoadjuvant or Adjuvant Therapy in NMSC for which populations?
C.L. (Lotje) Zuur
Netherlands Cancer Institute Antoni van Leeuwenhoek, Netherlands
10:40-11:00
Coffee Break, Poster Viewing & Visit the Exhibition
11:00-12:10
Session 8: Keynote Lectures
Chair: Alexander M.M. Eggermont, Netherlands
11:00-11:30
Keynote Lecture 6: New Vaccines for Melanoma: what is new and most promising?
Olivier Michielin
University Hospital Geneva, Switzerland
11:30-11:35
Discussion/Q&A
11:35-12:05
Keynote Lecture 7: Precision Immuno-Oncology: what are the complexities and promises
Olivier Michielin
University Hospital Geneva, Switzerland
12:05-12:10
Discussion/Q&A
12:10-13:00
Session 9: Prediction, Registration and Management of irAEs
Chair: Mario Mandalà, Italy
12:10-12:35
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
Lukas Flatz
University Hospital Tübingen, Germany
12:35-13:00
The New WHO Pathology Classification of Melanoma: Pros and Cons
Daniela Massi
University of Florence, Italy
13:00-14:00
Lunch Break, Poster Viewing & Visit the Exhibition
14:00-14:10
Industry Spotlight Sponsored by Sanofi
14:00-14:10
Skin Toxicities from Immune Checkpoint Blockade
Yevgeniy (Eugene) R. Semenov
Massachusetts General Hospital, Harvard Medical School, USA
14:10-15:30
Session 10: New Strategies in Advanced Melanoma
Chair: Alexander M.M. Eggermont, Netherlands
14:10-14:35
Prevention and screening of melanoma in Europe: 20 years of the Euromelanoma campaign
Veronique del Marmol
Hospital HUB (Hopital Erasme-Institut Jules Bordet), Université Libre de Bruxelles, Belgium
14:35-15:00
Current and Future Treatment Options for Brain Metastases
Anna Maria Di Giacomo
University of Siena, Italy
15:00-15:25
From IO Doublet Combos to Triplet Combos in Immunotherapy of Advanced Melanoma
Christian Blank
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Netherlands
15:25-15:30
Discussion/Q&A
15:30-16:00
Coffee Break, Poster Viewing & Visit the Exhibition
16:00-17:00
Session 11: Short Presentations by Young Investigators
Chair: Mario Mandalà, Italy
16:00-16:10
Artificial ultraviolet radiation and skin melanoma in Iceland and the Faroe Islands
16:10-16:20
Skin cancer risk in over 200.000 patients with hematologic malignancies in 30 years; a nationwide, population-based study in the Netherlands
16:20-16:30
Clinical use of the i31-GEP for SLNB for T1-T2a cutaneous melanoma significantly and safely reduces unnecessary procedures
16:30-16:40
Diagnosing and guiding non-surgical therapy of Basal Cell Carcinoma with combined Optical Coherence Tomography/Reflectance Confocal Microscopy
16:40-16:50
Retrospective real-life evaluation of outcome after discontinuation of anti-PD1 therapy for complete response cutaneous squamous cell carcinoma in patients over 75 years of age
16:50-17:00
Neoadjuvant atezolizumab in patients with surgically resectable advanced cutaneous squamous cell carcinoma
17:00-17:10
Poster Award Ceremony / Conclusions and Closure
Prof. Dr. Alexander M.M. Eggermont, Netherlands and Dr. Mario Mandalà, Italy | Congress Chairs
17:10
End of Congress
